The MedicX Fund Limited
28 February 2007
For immediate release 28 February 2007
MedicX Fund Limited
('MedicX Fund', 'the Fund' or 'the Company')
Acquisition of New Site
MedicX Fund, the specialist investor in modern purpose built primary healthcare
properties, which on 2 November 2006 listed on the Official List of the London
Stock Exchange today announces that it has, via its subsidiary MedicX Properties
V Ltd, entered into a fixed price forward funding agreement with Oakapple to
acquire a new medical centre at Alsager, Cheshire, for £8.68 million in cash.
The Fund is earning licence fee income during its development. The initial
rental income of the property will be £507,067 per annum and has been valued by
DTZ Debenham Tie Leung, valuers to the MedicX Fund at £8.80 million net of 5.75%
purchaser costs. This property is expected to be completed by April 2008.
Ends
For further information please contact:
MedicX Group +44(0) 1483 869500
Keith Maddin, Chairman
Mike Adams, Managing Director
Buchanan Communications +44(0) 20 7466 5000
Charles Ryland / Lisa Baderoon / Mary-Jane Johnson
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.